VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CRBPCorbus Pharmaceuticals Holdings, Inc.
$8.31$104M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCRBPEarnings History

CRBP logoCorbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$85M
● Net Loss
TTM EPS (Diluted)
$-6.35
Per share, diluted
YoY EPS Growth
-60.3%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-54.2%
Return on Assets-48.5%
Record Annual Net Income-$887FY2012
Record Quarterly EPS$0.90Q2 2019
Consecutive Profitable Years0years
Q1 2026
Net Income-$23M
EPS (Diluted)$-1.72
YoY Growth-60.3%Declining
QoQ Growth-11.7%Declining

Loading earnings history...

Corbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings Overview

As of June 23, 2026, Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported trailing twelve-month net income of -$85M, reflecting -60.3% year-over-year growth. The company earned $-6.35 per diluted share over the past four quarters.

Looking at the long-term picture, CRBP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$887 in fiscal 2012.

Corbus Pharmaceuticals Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including AGIO (-$423M net income, -764.0% margin), RCUS (-$369M net income, -142.9% margin), IMVT (-$506M net income), CRBP has comparable earnings metrics. Compare CRBP vs AGIO →

CRBP Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
CRBP logoCRBPCurrent
-$85M$-6.35--54.2%-60.3%—
AGIO logoAGIO
-$423M$-7.19-764.0%-30.2%-161.2%
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
ARQT logoARQT
-$2M$-0.02-4.3%-9.3%+88.8%
PRAX logoPRAX
-$327M$-11.31--45.8%-32.0%
Best in group
Lowest in group

CRBP Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$79M-95.3%-$85M$-5.90--
2024-$40M+9.9%-$49M$-3.68--
2023-$45M+20.1%-$45M$-10.31--
2022-$56M-22.6%-$35M$-10.15--
2021-$46M+59.1%-$56M$-11.13-5166.4%-6350.1%
2020-$111M-55.7%-$123M$-42.72-2826.1%-3119.2%
2019-$71M-28.3%-$77M$-33.55-197.7%-213.3%
2018-$56M-71.7%-$57M$-29.30-1154.5%-1176.8%
2017-$32M-62.1%-$33M$-19.38-1328.6%-1334.4%
2016-$20M-126.0%-$20M$-14.58-1046.3%-1045.6%
2015-$9M-248.4%-$9M$-8.47-1365.1%-1365.5%
2014-$3M-321.8%-$3M$-3.78--
2013$-602,350-67808.7%$-557,276$-0.70--
2012$-887-$-824$-3.82--

Download Data

Export CRBP earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CRBP — Frequently Asked Questions

Quick answers to the most common questions about buying CRBP stock.

What is CRBP earnings per share (EPS)?

CRBP trailing twelve-month (TTM) diluted EPS is $-6.35, reflecting -60.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Corbus Pharmaceuticals Holdings, Inc.'s net income?

Corbus Pharmaceuticals Holdings, Inc. (CRBP) trailing twelve-month net income is $-85M as of 2025. Earnings declined -60.3% year-over-year.

Is CRBP profitable?

CRBP is not currently profitable on a TTM basis, reporting a net loss of $-85M. Net margin is N/A. Investors should monitor for a return to profitability.

What is CRBP's earnings growth rate?

CRBP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are CRBP's profit margins?

Corbus Pharmaceuticals Holdings, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -54.2%.

Is CRBP growing earnings?

CRBP earnings are declining — EPS fell -60.3% year-over-year. TTM net income dropped to $-85M. This contrasts with the 5-year CAGR of N/A.

What was CRBP's best earnings year?

Corbus Pharmaceuticals Holdings, Inc.'s highest annual net income on record is $-887.00, achieved in fiscal year 2012. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were CRBP's earnings last quarter?

CRBP's most recent reported quarter was Q1 2026. Net income was $-23M with diluted EPS of $-1.72. For a full breakdown of all quarters, see the quarterly earnings table on this page.

CRBP Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view